Amlodipine/atorvastatin (Caduet®) is a once-daily fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

Amlodipine/atorvastatin (Caduet®) is a single-tablet, fixed-dose combination of the
dihydropyridine calcium channel antagonist amlodipine and the HMG-CoA reductase …

The AVALON study was a randomized, multicenter trial to assess the efficacy and safety of
coadministered amlodipine and atorvastatin in patients with hypertension and dyslipidemia …

Guidelines stress the importance of the simultaneous management of multiple
cardiovascular risk factors. This can in part be achieved by coadministration of lipid …

Hypertension (HTN) and dyslipidemia (DYS) commonly coexist. Patients with concurrent
HTN and DYS are at high risk of cardiovascular disease, yet most patients do not achieve …

Hypertension and dyslipidemia are two of the most commonly co-occurring cardiovascular
risk factors which together cause an increase in coronary heart disease-related events that …

The bioequivalence of combination tablets containing amlodipine besylate/atorvastatin
calcium with coadministered matching doses of amlodipine besylate and atorvastatin …

This review describes the clinical profile and rationale for the development of a single-pill
formulation of the calcium channel blocker amlodipine besylate, a blood-pressure--lowering …

In 2002, the World Health Organization estimated that over 58% of cardiovascular disease in
North America is due to 'both blood pressure and cholesterol higher than optimal' …

Cardiovascular diseases are the leading cause of death worldwide. Risk factors are rarely
seen individually, and the 2 most common and most frequently associated risk factors are …